Rep. Jefferson Shreve Sells Off Shares of Zoetis Inc. (NYSE:ZTS)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Zoetis stock on April 17th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.

Zoetis Price Performance

NYSE ZTS traded up $3.79 during trading on Thursday, reaching $158.71. The company's stock had a trading volume of 1,654,516 shares, compared to its average volume of 2,504,143. The stock has a market capitalization of $70.66 billion, a PE ratio of 29.02, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a fifty day moving average of $156.72 and a 200 day moving average of $165.71. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the company earned $1.38 EPS. Zoetis's revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZTS shares. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Stifel Nicolaus lowered their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $212.75.

Hedge Funds Weigh In On Zoetis

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Baird Financial Group Inc. increased its position in Zoetis by 1.4% in the first quarter. Baird Financial Group Inc. now owns 468,196 shares of the company's stock worth $77,088,000 after buying an additional 6,559 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its position in Zoetis by 4.2% in the first quarter. Pinnacle Wealth Planning Services Inc. now owns 4,052 shares of the company's stock worth $667,000 after buying an additional 162 shares in the last quarter. Vident Advisory LLC increased its position in Zoetis by 135.3% in the first quarter. Vident Advisory LLC now owns 81,141 shares of the company's stock worth $13,360,000 after buying an additional 46,659 shares in the last quarter. Evergreen Capital Management LLC grew its position in shares of Zoetis by 31.8% during the first quarter. Evergreen Capital Management LLC now owns 3,106 shares of the company's stock worth $511,000 after purchasing an additional 749 shares in the last quarter. Finally, WPG Advisers LLC purchased a new stake in shares of Zoetis during the first quarter worth about $71,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.